INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
SEC FORM 4/Grant or awardVerified data

Scott Robert A reported ARQT

Director · Arcutis Biotherapeutics, Inc. · Common Stock

Side
A
Value
—
Shares
2,819
Price
—
Executed
Oct 23, 2026
Disclosed
Oct 28, 2026
Disclosure timeline5 days from execution to publication · legal deadline 2 business days
Oct 23 executedOct 28, 2026 disclosed

ARQT · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
15/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing+6 / 15

    Disclosed 3 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ARQT

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    8
    MM
    Matsuda MasaruEVP, Chief Legal Officer
    ARQTArcutis Biotherapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$39K
    1,219 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    30
    WT
    Watanabe ToddDirector, See Remarks
    ARQTArcutis Biotherapeutics, Inc.
    Open-market sale
    		SELL$139K
    4,377 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    24
    BP
    Burnett PatrickEVP, Chief Medical Officer
    ARQTArcutis Biotherapeutics, Inc.
    Open-market sale
    		SELL$30K
    943 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    MM
    Matsuda MasaruEVP, Chief Legal Officer
    ARQTArcutis Biotherapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    40.0K sh
    		Nov 4, 2026Nov 4, 2026
    traded Nov 4, 2026
    		+0dSEC FORM 4

    Evidence

    25
    MM
    Matsuda MasaruEVP, Chief Legal Officer
    ARQTArcutis Biotherapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.37M
    40.0K sh
    		Nov 4, 2026Nov 4, 2026
    traded Nov 4, 2026
    		+0dSEC FORM 4

    Evidence

    3
    MM
    Matsuda MasaruEVP, Chief Legal Officer
    ARQTArcutis Biotherapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$146K
    40.0K sh
    		Nov 4, 2026Nov 4, 2026
    traded Nov 4, 2026
    		+0dSEC FORM 4

    Evidence

    15
    SA
    Scott Robert ADirector
    ARQTArcutis Biotherapeutics, Inc.
    Grant or award
    		A—
    20.5K sh
    		Oct 23, 2026Oct 28, 2026
    traded Oct 23, 2026
    		+5dSEC FORM 4

    Evidence

    15
    SA
    Scott Robert ADirector
    ARQTArcutis Biotherapeutics, Inc.
    Grant or award
    		A—
    8,663 sh
    		Oct 23, 2026Oct 28, 2026
    traded Oct 23, 2026
    		+5dSEC FORM 4

    Evidence

    1
    MM
    Matsuda MasaruSee Remarks
    ARQTArcutis Biotherapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$92K
    3,674 sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    10
    MM
    Matsuda MasaruSee Remarks
    ARQTArcutis Biotherapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$250K
    9,989 sh
    		Sep 8, 2026Sep 10, 2026
    traded Sep 8, 2026
    		+2dSEC FORM 4

    Evidence

    24
    CT
    Curran TerrieDirector
    ARQTArcutis Biotherapeutics, Inc.
    Option exercise
    		M$233K
    27.1K sh
    		Aug 27, 2026Aug 28, 2026
    traded Aug 27, 2026
    		+1dSEC FORM 4

    Evidence

    40
    CT
    Curran TerrieDirector
    ARQTArcutis Biotherapeutics, Inc.
    Open-market sale
    		SELL$279K
    11.1K sh
    		Aug 27, 2026Aug 28, 2026
    traded Aug 27, 2026
    		+1dSEC FORM 4

    Evidence

    20
    CT
    Curran TerrieDirector
    ARQTArcutis Biotherapeutics, Inc.
    Option exercise
    		M$84K
    11.1K sh
    		Aug 27, 2026Aug 28, 2026
    traded Aug 27, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CT
    Curran TerrieDirector
    ARQTArcutis Biotherapeutics, Inc.
    Option exercise
    		M—
    11.1K sh
    		Aug 27, 2026Aug 28, 2026
    traded Aug 27, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CT
    Curran TerrieDirector
    ARQTArcutis Biotherapeutics, Inc.
    Option exercise
    		M—
    27.1K sh
    		Aug 27, 2026Aug 28, 2026
    traded Aug 27, 2026
    		+1dSEC FORM 4

    Evidence

    44
    CT
    Curran TerrieDirector
    ARQTArcutis Biotherapeutics, Inc.
    Open-market sale
    		SELL$677K
    27.1K sh
    		Aug 27, 2026Aug 28, 2026
    traded Aug 27, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BP
    Burnett PatrickSee Remarks
    ARQTArcutis Biotherapeutics, Inc.
    Option exercise
    		M$30K
    8,300 sh
    		Aug 11, 2026Aug 13, 2026
    traded Aug 11, 2026
    		+2dSEC FORM 4

    Evidence

    24
    BP
    Burnett PatrickSee Remarks
    ARQTArcutis Biotherapeutics, Inc.
    Open-market sale
    		SELL$220K
    8,300 sh
    		Aug 11, 2026Aug 13, 2026
    traded Aug 11, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BP
    Burnett PatrickSee Remarks
    ARQTArcutis Biotherapeutics, Inc.
    Option exercise
    		M$24K
    6,700 sh
    		Aug 12, 2026Aug 13, 2026
    traded Aug 12, 2026
    		+1dSEC FORM 4

    Evidence

    24
    BP
    Burnett PatrickSee Remarks
    ARQTArcutis Biotherapeutics, Inc.
    Open-market sale
    		SELL$175K
    6,700 sh
    		Aug 12, 2026Aug 13, 2026
    traded Aug 12, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001628280-26-067898
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 23, 2026
    Published
    Oct 28, 2026
    Ingested by INSIDER
    Nov 5, 02:09 UTC
    Last re-read
    Nov 5, 02:09 UTC

    Extracted facts

    Filer
    Scott Robert A
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Arcutis Biotherapeutics, Inc.
    Ticker
    ARQT
    Shares
    2,819
    Price per share
    $0
    Execution date (reported)
    Oct 23, 2026
    Owned after transaction
    2,819 shares
    Days from execution to publication
    5

    What this establishes

    Scott Robert A filed this Form 4 reporting a grant or award of ARQT on Oct 23, 2026. It became public on Oct 28, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Scott Robert Acik:0001248520
    Issuer
    Arcutis Biotherapeutics, Inc.cik:0001787306

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.